Its weight-loss effects are primarily achieved through several mechanisms, including central appetite regulation via hypothalamic pathways enhancing satiety, delayed gastric emptying that prolongs postprandial fullness, improvement of insulin sensitivity and metabolic homeostasis, and reduction of visceral and hepatic fat depots, which may alleviate respiratory mechanical burden and metabolic stress in OSAS (34)
While the specific mechanism may differ slightly between pregnancy-related and GLP-1-related nausea, the brainstem pathways targeted are substantially similar, which provides a reasonable pharmacological basis for using B6 alongside semaglutide
Tirzepatide, a novel dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, is currently being developed for the treatment of type 2 diabetes
3 Confirm employer benefit design with HR On commercial employer plans, weight-loss drug coverage depends on whether your employer purchased the anti-obesity benefit